Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNA5 | P30532 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17835010 | 0.88 | PDK2 (0.41) | CYP11B2CYP11B1CYP19A1PDK2 | |
| SCHEMBL17835012 | 0.84 | CYP11B1 (0.41) | CYP11B2CYP11B1CYP17A1CYP19A1PDK2 | |
| SCHEMBL17834989 | 0.82 | PDK2 (0.40) | PDK2MAPK1 | |
| SCHEMBL29398870 | 0.79 | PDK2 (0.46) | PDK2MAPK1 | |
| SCHEMBL15729905 | 0.79 | PDK2 (0.46) | PDK2MAPK1 | |
| SCHEMBL31172126 | 0.79 | PDK2 (0.46) | PDK2MAPK1 | |
| SCHEMBL27193176 | 0.79 | CYP11B2 (0.50) | CYP11B2CYP11B1CYP17A1CYP19A1FLT3 | |
| SCHEMBL17835063 | 0.78 | PDK2 (0.38) | PDK2 | |
| SCHEMBL21442842 | 0.78 | PDK2 (0.43) | CYP11B2CYP11B1CYP19A1PDK2 | |
| SCHEMBL21442824 | 0.77 | PGR (0.37) | CYP19A1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683453-B2 | Organic compounds with soluble groups | MERCK PATENT GMBH (DE) | 2020-06-16 | — | — | US | disclosed |
| EP-3230403-B1 | ORGANIC COMPOUNDS WITH SOLUBLE GROUPS | MERCK PATENT GMBH (DE) | 2019-10-09 | — | — | EP | disclosed |
| WO-2016091353-A1 | ORGANIC COMPOUNDS WITH SOLUBLE GROUPS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683453-B2 | Organic compounds with soluble groups | SLCO4C1, SLCO1B3, SLCO2B1 | CYP11B2 228/4885CYP11B1 348/4885CYP17A1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.